linjc16/ctgov huggingface dataset:
Dose-effect Relationship Between microRNAs in Peripheral Blood and Radiation Injury

Study Overview
=================
Brief Summary
-----------------
Rapid and accurate assessment of radiation injury dose is the key to success in early treatment and an urgent issue to be solved in clinical medicine.Researches showed that the expression of the microRNAs in human peripheral blood had much correlation with radiation injury resulted from different dosages of radiation.In this study,acute leukemic patients who will be pretreated by whole-body radiation are taked as the object of study,and biochip technology are adopted to detect the expression levels of the microRNAs in subject peripheral blood before-and-after radiation,and different expression is tested and Bioinformatics prediction,to evaluate the correlation between radiation injury dose and expression levels of the microRNAs in human peripheral blood.

Official Title
-----------------
Study on Dose-effect Relationship Between Radiation Injury Dose and Expression of Associated microRNAs in Human Peripheral Blood

Conditions
-----------------
Radiation Injuries, Experimental

Intervention / Treatment
-----------------
* Radiation: 5 Gy or 10 Gy units of whole-body radiation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: subjects who suffer from acute leukemic subjects who accept chemotherapy within one month and will be pretreated by whole-body irradiation peripheral blood cells of subjects are approximate to those of healthy person aged between 18 and 50 years old subjects who are competent to give written informed consent subjects without other systemic diseases Exclusion Criteria: subjects who suffer from serious other systemic diseases subjects who are unwilling or unable to cooperate with this clinical study other serious cases that probably hinder this clinical study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: 5 Gy or 10 Gy units of whole-body radiation|8 subjects will be received 5 Gy units of whole-body radiation or 10 Gy units of whole-body radiation.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| expression levels of the microRNAs | the expression levels of the microRNAs in human peripheral blood before radiation，12 hours after radiation and 24 hours after radiation | 12 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Radiation Injuries, microRNA
Could Algometric Assessment be Effective to Adjust Postoperative Analgesic Requirement?

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the correlation between preoperative algometer score and the amount of postoperative analgesic consumption. The algometer score of the patients will be recorded in the preoperative period. In postoperative period, the analgesic consumption rate will record and compare with the algometer score.

Detailed Description
-----------------
The aim of this study is to define the correlation between preoperative algometer score and the analgesic consumption rate. A total of 80 patients whose undergo septoplasty or septorhinoplasty will be included in this study. After preoperative examination, a positive pressure using algometer device will be performed until minimal pain is felt. In postoperative period, the amount of analgesic consumption of the patient will record and compare with the algometer score.

Official Title
-----------------
Could Algometric Assessment be Effective to Adjust Postoperative Analgesic Requirement?

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Device: Algometer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients those undergo septoplasty or septorhinoplasty Exclusion Criteria: Hypertension Diabetes mellitus type 1 or 2 Continuous use of analgesics Patients whose do not accept to participate in the study Patients those reoperated for bleeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Algometer<br>Algometer used patients | Device: Algometer<br>* Algometer performed patients<br>* Other names: J-Tech Commander - Algometer;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Algometer score | Score obtained from the Algometer device | In one hour before the operation up to 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analgesic consumption | The amount of analgesic consumption | In the first 24 hours after the operation up to 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pain management
A Study of RO6799477 in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This single-center, randomized, double-blind, placebo-controlled, single dose study will investigate the safety, pharmacokinetics, pharmacodynamics of RO6799477 in healthy volunteers.

Official Title
-----------------
A Single-center, Randomized, Double-blind, Placebo-controlled, Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6799477 Following Oral Administration of Single Ascending Doses in Healthy Volunteers.

Conditions
-----------------
Healthy Volunteer

Intervention / Treatment
-----------------
* Drug: RO6799477


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male healthy volunteers, aged 18-45 years, inclusive Male volunteers with female partner of childbearing potential must agree to use an effective form of birth control during the study and for 3 months after discontinuation of treatment. Body Mass index (BMI) of 18-30 kg/m2, inclusive Exclusion Criteria: Infection with human immunodeficiency virus antibody (HIV 1 and 2), Hepatitis B, hepatitis C Positive testing for drugs of abuse Any history of alcohol and/or drug of abuse addiction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single oral dose group<br> | Drug: RO6799477<br>* Single doses of RO6799477<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Part 1: Safety: Incidence of adverse events |  | 18 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Part 1 and 2: Pharmacokinetics: plasma concentration of RO6799477 |  | Pre-dose, Day 1, 2, 3, 4 |
Optimizing IVF Treatment - the Impact of Time-lapse Culture and Preimplantation Factor (PIF) on Embryo Development.

Study Overview
=================
Brief Summary
-----------------
The aims of this study are to evaluate: the possible effect of time-lapse culture from day zero (day of oocyte retrieval) on fertilisation rates and embryo quality in standard IVF. the association between PIF status in embryo culture medium and embryo quality assessed by standard subjective parameters and morphokinetic development.

Official Title
-----------------
Optimizing IVF Treatment - the Impact of Time-lapse Culture and Preimplantation Factor (PIF) on Embryo Development.

Conditions
-----------------
In Vitro Fertilization, Assisted Reproductive Techniques

Intervention / Treatment
-----------------
* Procedure: Day 0 denudation and time lapse culture on IVF-oocytes.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Standard IVF treatment Body mass Index (BMI) between 18 and 30 couples in which the male partner has normal sperm concentration and motility according to the World Health Organization (WHO, 2010) Exclusion Criteria: - Patients with less than four oocytes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Day 0 - Study arm<br>Day 0 denudation and time lapse culture on IVF-oocytes.: After insemination the oocytes will subsequently be denuded and cultured in the EmbryoScope (day 0). The embryo culture media will be collected at day 2-5. | Procedure: Day 0 denudation and time lapse culture on IVF-oocytes.<br> <br> |
| No Intervention: Day 1 - control arm<br>After insemination oocytes in the control group will be incubated in a standard incubator overnight. On day 1 the oocytes in the will be denuded and further cultured in the EmbryoScope. The embryo culture media will be collected at day 2-5. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Embryo Quality |  | Day 0-5 after oocyte pick-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fertilisation rate |  | Day 1 after oocyte pick-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IVF, Embryo Quality, Time Lapse Culture, Preimplantation factor
Fast Tracking Impact on Fentanyl Consumption and Parents Satisfaction

Study Overview
=================
Brief Summary
-----------------
The investigators are measuring fentanyl consumption in micrograms used during anesthesia for patients on fast track congenital cardiac surgeries

Detailed Description
-----------------
The investigators are measuring fentanyl consumed for both fast track and conventional corrective cardiac surgeries and also parents Parental Perceptions satisfaction with early child communication in ICU and impact of caudal anesthesia on extubation time our 2ry outcomes are the hospital and ICU length of stay

Official Title
-----------------
Fast Tracking Impact on Fentanyl Consumption and Parents Satisfaction in Non Complex Cardiac Surgery

Conditions
-----------------
Fentanyl Adverse Reaction, Caudal Anesthesia

Intervention / Treatment
-----------------
* Drug: Fentanyl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed with congenital cardiac anomaly for surgical correction. age limit: child 3months of age to 18 years Exclusion Criteria: patients with any o the following: emergency surgeries redo surgeries complex surgeries patients weight less than 3kg

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| early extubation<br>the patients extubated in O.R or within 2 hours in the ICU | Drug: Fentanyl<br>* amount of fentanyl used in both groups<br>|
| late extubation<br>the patients extubated after 2 hours from O.R | Drug: Fentanyl<br>* amount of fentanyl used in both groups<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fentanyl consumption | amount of fentanyl used in microgram | during the procedure (corrective surgery) | 
| parents satisfaction: questionnare | questionnare for parents satisfaction by early child communication | after discharge from the ICU up to 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intensive care length of stay | number of days in ICU | after departure from operation room until ward discharge up to 3 weeks | 
| hospital length of stay | total number of days spent in hospital | from admission until home discharge up to 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fast track, congenital cardiac surgery, caudal, fentanyl
Cohort Study Comparing Short Daily Hemodialysis (HD) With Conventional HD

Study Overview
=================
Brief Summary
-----------------
This study is examining the effects of short daily hemodialysis on platelet function, fluid volume control, arterial stiffness and patient quality of life, as compared to conventional hemodialysis.

Detailed Description
-----------------
Bleeding is a common cause of morbidity and mortality in patients with end stage renal disease. A major cause of uremic bleeding is due to platelet dysfunction. It has been theorized that in renal failure, toxins accumulate, some of which inhibit primary hemostasis. All aspects of normal platelet function are affected. Platelet function has previously been difficult to quantify but recently a novel test, the platelet function analyzer (PFA-100) has been determined to be both sensitive and specific in assessing platelet function. Conventional hemodialysis (CHD) has been shown to partially correct thrombocytopathy. Enhanced uremic clearance can now be attained through the use of short daily hemodialysis (SDHD). Cardiovascular disease is the most common cause of mortality in dialysis patients, accounting for 40% of deaths. Volume overload is associated with high blood pressure, left ventricular hypertrophy and elevated markers of inflammation and these factors have been associated with increased cardiovascular mortality. SDHD has been shown to control blood pressure and limit volume expansion. Pulse wave velocity (PWV) has been used to assess arterial compliance and reduction of arterial elasticity of large and small arteries which have been associated with cardiovascular outcomes.

Official Title
-----------------
Cohort Study Examining the Effects of Short Daily Hemodialysis As Compared to Conventional Hemodialysis in Outpatients Treated at St Joseph's Healthcare, Hamilton

Conditions
-----------------
End-stage Renal Disease, Thrombocytopathy, Cardiovascular Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is enrolled in short daily hemodialysis program Patient is minimum of 18 years old Exclusion Criteria: Patient is unable to consent due to language barrier Patient is unable to consent due to cognitive difficulties Patient refuses consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>conventional HD | |
| 2<br>short daily HD | |
| 3<br>PD | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemodialysis, platelet function analyzer, bioimpedance, pulse wave velocity, end stage renal disease
Heart Disease and the Black Health Disadvantage

Study Overview
=================
Brief Summary
-----------------
To utilize national population data sets prepared by the National Center for Health Statistics, to (1) examine the current Black disadvantage in cardiovascular (CV) health, (2) explore potential clinical and epidemiologic causes, (3) incorporate emerging knowledge of new risk factors and (4) compare trends in medical treatment and risk factors for the four sex-race groups.

Detailed Description
-----------------
BACKGROUND: The Black health disadvantage remains a pressing public health issue in the United States. According to the Department of Health and Human Services 'Black and Minority Health Report', 65,000 excess deaths occur each year among Blacks when compared to the mortality experience of whites. Cardiovascular diseases make by far the largest contribution to this loss of life, accounting for over 30 percent of the excess. Despite improvements in CV mortality for all four major sex-race groups during the 1970's, the trends in heart disease in the United States began to diverge. A 50 percent slowing of the decline in coronary mortality occurred among Blacks from 1978-1986, compared to whites, and the gap in life expectancy between the races has widened. As noted in the 'Report', despite the widespread recognition of the importance of the problem, our knowledge regarding the causes of these differentials in CV disease was inadequate. To address this problem, the Report recommended support for 'innovative uses of current data' and 'cross-comparisons from different data sets', emphasizing the unique contribution population-based studies can make to 'understanding the health status and needs of minority populations'. Given the deterioration of the Black health status relative to the majority population, these recommendations took on new urgency. DESIGN NARRATIVE: Several separate analyses were conducted of prevalence surveys, epidemiologic followup studies, hospitalization surveys and vital statistics. These separate analyses were subsequently combined into a comprehensive description of the clinical and epidemiologic determinants of the Black CV disadvantage, and its future trends. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Coronary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Serological Response to Retreatment of Serofast Early Syphilis Cases With Benzathine Penicillin

Study Overview
=================
Brief Summary
-----------------
A continuing challenge to determining the response to treatment of early syphilis (primary, secondary, early latent syphilis) is exemplified by the substantial proportion of patients who fail to achieve serological cure and remain serofast. Although retreatment is often done in clinical practice, optimal management remains uncertain due to the paucity of data regarding serological response to retreatment and long-term outcomes. Furthermore, the investigators cannot rule out that the gradually increasing seroreversion/serological cure rates may have been due to the natural decline in rapid plasma regain (RPR) titers after initial therapy, rather than due to the additional dose of benzathine penicillin. Thus, the investigators would like to conduct a clinical trial to compare the serological response rates of serofast early syphilis cases retreated with three doses benzathine penicillin and absence of any retreatment (control group).

Official Title
-----------------
Randomized, Clinical Trial to Compare the Serological Response Rates of Serofast Early Syphilis Cases Retreated With Three Doses Benzathine Penicillin and Absence of Any Retreatment

Conditions
-----------------
Syphilis

Intervention / Treatment
-----------------
* Drug: benzathine penicillin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Early Syphilis Cases Determined to Be Serofast at 6 Months after Initial Treatment Exclusion Criteria: Human immunodeficiency virus (HIV)-infected Baseline serology showed a nonreactive RPR test follow-up is inadequate Allergic to penicillin Pregnant woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Retreatment group<br>Serofast early syphilis cases retreated with three doses benzathine penicillin | Drug: benzathine penicillin<br> <br> |
| No Intervention: Control group<br>Absence of any retreatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rapid plasma regain titer |  | 6 months after retreatment |
Effect of Tetrix on Alleviation of Burning,Itching Associated With Lesions of Contact Dermatitis

Study Overview
=================
Brief Summary
-----------------
To determine if Tetrix Cream, when applied to the skin lesions on patients with contact dermatitis, improves the symptoms of burning and itching.

Official Title
-----------------
An Open Label Study of the Therapeutic Effects of Tetrix Cream in Allergic Contact and Irritant Contact Dermatitis

Conditions
-----------------
Contact Dermatitis

Intervention / Treatment
-----------------
* Device: Tetrix
* Device: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal subjects with sensitivity to nickel Subjects with hand eczema Exclusion Criteria: under 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Experimental | Device: Tetrix<br>* Twice daily topical application<br>|
| Placebo Comparator: 2<br>Placebo | Device: Placebo<br>* Twice daily topical application<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in symptoms of burning and itching. |  | after 14 days of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tetrix cream, contact dermatitis, effect on burning and itching